VAISHALI Stock Overview
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally.
Vaishali Pharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹86.35|
|52 Week High||₹119.30|
|52 Week Low||₹28.95|
|1 Month Change||4.86%|
|3 Month Change||2.74%|
|1 Year Change||95.58%|
|3 Year Change||213.29%|
|5 Year Change||n/a|
|Change since IPO||122.48%|
Recent News & Updates
Should You Be Adding Vaishali Pharma (NSE:VAISHALI) To Your Watchlist Today?
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
|VAISHALI||IN Pharmaceuticals||IN Market|
Return vs Industry: VAISHALI exceeded the Indian Pharmaceuticals industry which returned -12% over the past year.
Return vs Market: VAISHALI exceeded the Indian Market which returned 8.3% over the past year.
|VAISHALI Average Weekly Movement||5.1%|
|Pharmaceuticals Industry Average Movement||5.9%|
|Market Average Movement||6.3%|
|10% most volatile stocks in IN Market||9.0%|
|10% least volatile stocks in IN Market||4.1%|
Stable Share Price: VAISHALI is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: VAISHALI's weekly volatility (5%) has been stable over the past year.
About the Company
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers active pharmaceutical ingredients (APIs), including antibiotics, anti-ulcer, anti-inflammatory/analgesic/anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, anti-diarrheal/anti-protozoal/anti-parasitic, anti-viral, anti-epileptic, anti-asthmatic, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helmintic drugs, as well as excipients, topical steroids, corticosteroids, and enzymes. The company also provides formulation products, such as antibiotics/antibacterial, anti-platelet, laxative, anti-ulcer/enzyme, anti-asthmatic, anti-malarial, anti-cold/anti-allergic/anti-viral, anti-psychotic, anti-fungal, anti-inflammatory/analgesic/anti-pyretic, anti-diabetic, cardiac, vitamins, topical steroids/corticosteroids, and other formulations.
Vaishali Pharma Fundamentals Summary
|VAISHALI fundamental statistics|
Is VAISHALI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VAISHALI income statement (TTM)|
|Cost of Revenue||₹637.61m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||4.48|
|Net Profit Margin||6.08%|
How did VAISHALI perform over the long term?See historical performance and comparison
Is VAISHALI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VAISHALI?
Other financial metrics that can be useful for relative valuation.
|What is VAISHALI's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does VAISHALI's PE Ratio compare to its peers?
|VAISHALI PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
531739 Gennex Laboratories
524506 Coral Laboratories
524202 Lactose (India)
524396 Biofil Chemicals and Pharmaceuticals
VAISHALI Vaishali Pharma
Price-To-Earnings vs Peers: VAISHALI is good value based on its Price-To-Earnings Ratio (19.3x) compared to the peer average (46.2x).
Price to Earnings Ratio vs Industry
How does VAISHALI's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
Price-To-Earnings vs Industry: VAISHALI is good value based on its Price-To-Earnings Ratio (19.3x) compared to the Indian Pharmaceuticals industry average (22.6x)
Price to Earnings Ratio vs Fair Ratio
What is VAISHALI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||19.3x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate VAISHALI's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of VAISHALI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: VAISHALI (₹86.35) is trading above our estimate of fair value (₹18.78)
Significantly Below Fair Value: VAISHALI is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Vaishali Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vaishali Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
How has Vaishali Pharma performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VAISHALI has high quality earnings.
Growing Profit Margin: VAISHALI's current net profit margins (6.1%) are higher than last year (3.2%).
Past Earnings Growth Analysis
Earnings Trend: VAISHALI's earnings have grown significantly by 49.3% per year over the past 5 years.
Accelerating Growth: VAISHALI's earnings growth over the past year (154.5%) exceeds its 5-year average (49.3% per year).
Earnings vs Industry: VAISHALI earnings growth over the past year (154.5%) exceeded the Pharmaceuticals industry -0.3%.
Return on Equity
High ROE: VAISHALI's Return on Equity (17.9%) is considered low.
Discover strong past performing companies
How is Vaishali Pharma's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: VAISHALI's short term assets (₹764.3M) exceed its short term liabilities (₹519.4M).
Long Term Liabilities: VAISHALI's short term assets (₹764.3M) exceed its long term liabilities (₹33.3M).
Debt to Equity History and Analysis
Debt Level: VAISHALI's net debt to equity ratio (73.8%) is considered high.
Reducing Debt: VAISHALI's debt to equity ratio has reduced from 266.2% to 79% over the past 5 years.
Debt Coverage: VAISHALI's debt is not well covered by operating cash flow (6.3%).
Interest Coverage: VAISHALI's interest payments on its debt are well covered by EBIT (3.1x coverage).
Discover healthy companies
What is Vaishali Pharma current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VAISHALI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VAISHALI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VAISHALI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VAISHALI's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as VAISHALI has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Hemant Pathak (61 yo)
Mr. Hemant Damodar Pathak serves as Chief Executive Officer of Vaishali Pharma Limited May 26, 2020. He has good experience in the field International Business Development as exposure to more than 90 count...
Experienced Management: VAISHALI's management team is considered experienced (2.2 years average tenure).
Experienced Board: VAISHALI's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Vaishali Pharma Limited's employee growth, exchange listings and data sources
- Name: Vaishali Pharma Limited
- Ticker: VAISHALI
- Exchange: NSEI
- Founded: 1989
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹910.665m
- Shares outstanding: 10.55m
- Website: https://www.vaishalipharma.com
Number of Employees
- Vaishali Pharma Limited
- 706 to 709, Aravalli Business Center
- 7th Floor
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/16 00:00|
|End of Day Share Price||2022/08/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.